Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat + venetoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed AML unfit for intensive chemotherapy
2019-003117-33Phase 2Active
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Pevonedistat + venetoclax + azacitidine with Venetoclax + azacitidine (2 arms). Primary endpoint: Event-free survival. Started Apr 2020; status: active.
02
Drugs
pevonedistatvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-003117-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003117-33.